Charles River Drops WuXi PharmaTech Days Before Crucial Shareholder Vote; What Does the Future Hold For Both Firms?
This article was originally published in The Pink Sheet Daily
Executive Summary
Left at the altar by the U.S. CRO, WuXi gets a $30 million break up fee while Charles River likely will continue looking to build out its business in ways more appealing to shareholders.
You may also be interested in...
Impromptu Objections Filed With SEC Could Threaten Charles River's Proposed Merger With China's Leading CRO
BEIJING - A New York-headquartered money management outfit that is the largest shareholder in Charles River Laboratories International has unexpectedly thrown up a potential blockade in the drug research firm's $1.6 billion proposal to acquire China's WuXi PharmaTech
WuXi PharmaTech Founder Ge Li Says Upcoming Merger With Charles River Is Part Of Globalization Of The Drive To Save Lives
BEIJING - The chief executive officer of Shanghai-headquartered WuXi PharmaTech, Ge Li, said that a planned merger with Massachusetts-based contract research organization Charles River could help spark a "revolution" in early-stage drug research in China
Covance, WuXi Abandon Plans To Create Joint Drug Testing Facility In China
BEIJING - Just three months after unveiling plans to create a joint venture facility for preclinical drug testing services on China's east coast, the Shanghai-headquartered WuXi PharmaTech and and Princeton, N.J.-based Covance have called off the deal